The combination of a revenue beat, strong EPS growth, and upward guidance revision is a clear positive catalyst. The $22M debt prepayment signals improving balance sheet health. Watch for continued margin expansion and cash flow generation as the company executes on its 2026 plan. The stock has historically responded well to earnings beats (T+20 avg +5.72%).
Price Chart
Executive Summary
Bioventus reported Q1 2026 revenue of $132.1M (+6.6% YoY) and GAAP EPS of $0.04, improving from a -$0.04 loss in the prior year. The company raised its full-year 2026 Adjusted EPS guidance to $0.75-$0.79 and Cash from Operations guidance to $84M-$89M, while reaffirming revenue guidance of $600M-$610M. The beat on consensus estimates and upward guidance revision signal accelerating operational momentum and debt reduction progress.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $132.1M (+6.6% YoY) vs consensus $129.9M
- GAAP EPS of $0.04 vs -$0.04 YoY; Non-GAAP EPS of $0.15 vs $0.08 YoY (+88%)
- Adjusted EBITDA of $23.9M (+24% YoY)
- Raised FY2026 Adjusted EPS guidance to $0.75-$0.79 (from $0.73-$0.77)
- Raised FY2026 Cash from Operations guidance to $84M-$89M (from $82M-$87M)
- Reaffirmed FY2026 revenue guidance of $600M-$610M (+6-7% growth)
- Made $22M discretionary principal prepayment on term loan in March 2026
- Cash from operations of $8.9M vs -$19.3M cash outflow in prior-year period
Financial Impact
Q1 revenue beat consensus by ~$2.2M; Non-GAAP EPS of $0.15 represents an 88% YoY increase; FY2026 Adjusted EPS guidance raised by $0.02 at midpoint
Risk Factors
- Revenue growth partially driven by a $4.2M favorable one-time rebate benefit from a billing process change
- Restructuring costs of $454K in the quarter indicate ongoing cost optimization
- Cash balance declined to $35.8M from $51.2M at year-end due to debt prepayment
- Guidance assumes continued above-market growth in a competitive medical device market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001665988-26-000026 |
| Document: bvs-20260506.htm | 0001665988-26-000026 |
| Document: 0001665988-26-000026-index-headers.html | 0001665988-26-000026 |
| Document: 0001665988-26-000026-index.html | 0001665988-26-000026 |
| Document: 0001665988-26-000026.txt | 0001665988-26-000026 |
| 8-K Data (Synthetic) | 0001665988-26-000026 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 6w ago | Institutional Cluster | $13.88 $13.16 | ▼ −5.19% | ▼ −3.66% | $13.13 (−5.40%) |
Aug 5, 2026 8w ago | 8-K | $15.26 $14.37 | ▼ −5.83% | ▼ −5.23% | $13.13 (−13.96%) |
Aug 5, 2026 8w ago | Press Release | $15.26 $14.37 | ▼ −5.83% | ▼ −5.23% | $13.13 (−13.96%) |
Jun 11, 2026 16w ago | Institutional Cluster | $8.68 $12.22 | ▼ −40.78% | ▼ −38.89% | $13.13 (−51.27%) |
Jun 2, 2026 17w ago | Press Release | $8.11 $9.85 | ▼ −21.45% | ▼ −23.02% | $13.13 (−61.90%) |
May 21, 2026 19w ago | 8-K | $9.28 $8.99 | ▼ −3.13% | ▼ −1.71% | $13.13 (+41.49%) |
May 8, 2026 21w ago | Court Ruling | $10.50 $9.04 | ▼ −13.90% | ▼ −13.93% | $13.13 (+25.05%) |
May 6, 2026 21w ago | 8-K | $10.92 $8.55 | ▼ −21.70% | ▼ −24.48% | $13.13 (+20.24%) |
May 6, 2026 21w ago | Press Release | $10.92 $8.55 | ▼ −21.70% | ▼ −24.48% | $13.13 (+20.24%) |
Apr 28, 2026 22w ago | Press Release | $9.67 $8.87 | ▼ −8.27% | ▼ −14.32% | $13.13 (+35.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access